During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
CASE SUMMARY
History and presentation:
Comorbidities:
Medications:
Status:
Six months later:
Diagnostic workup:
Targeted Oncology: In patients with relapsed del(17p) chronic lymphocytic leukemia (CLL) initially given venetoclax, would you continue this therapy indefinitely?
MARC S. HOFFMANN, MD: My take on it, is that there is no good high-quality data for the long-term administration of venetoclax. The initial study looking at [patients with] del(17p) CLL that led to the monotherapy indication is all we have, and that data is now older.1 It's not reflective of current practice patterns. Most of those patients have not had a BTK inhibitor, for instance, as it's not given in conjunction with anti-CD20 therapy.
What is the reasoning behind your decision?
In the modern era, all the data we have is either 1 year or 2 years of treatment if you're giving venetoclax plus anti-CD20 therapy on-label. There are data that giving it continuously does allow for the emergence of resistance mutations.2 Now, if you look at the response kinetics of venetoclax and if you look at a BTK inhibitor, when you start ibrutinib [Imbruvica], or zanubrutinib [Brukinsa], or acalabrutinib [Calquence], it doesn't matter which [BTK inhibitor], you get slow debulking over years...and a long-term response. Until they develop a resistance mutation [while on the BTK inhibitor], or that patient starts to progress, every day that they're on therapy, they're getting into a deeper remission.... When you look at venetoclax, in the first couple months…the disease rapidly debulks and then [the patient gets] extra benefit while they stay on the drug. But it's not one of these drugs where they can stay on long term and get a continuous response.
Please describe the bassline characteristics of patients on the phase 3 ALPINE trial (NCT03734016).
There were a good number of patients who had a del(17p)...and it comprised around 20% of the population [in each arm of the study].3 In the zanubrutinib arm, 22.9% had either a TP53 mutation, del(17p), or both [compared with 23.1% in the ibrutinib arm]. The mutated status was less common because it was a relapsed/refractory patient population. However, patients with a complex karyotype were reasonably well represented, but data were missing for over 30% in either arm.
Most of these patients [in either arm] had 1 line of treatment, although there were some patients who were more heavily pretreated. A lot of these patients were BTK naive and the majority of them had had an anti-CD20 therapy [83.8%], while [79.5%] had prior chemoimmunotherapy and a minority of patients had previous BCL2 inhibitors [2.1%] or P13K inhibitors [3.4%].3
What was the long-term progression-free survival (PFS) observed in this study?
We have long-term data going out to 3 years that now indicates a sustained PFS benefit with zanubrutinib over the ibrutinib....4 At a median follow up of 36.3 months, the PFS benefit was sustained [in 65.8% of patients on zanubrutinib compared with 54.3% on ibrutinib (HR, 0.67; 95% CI, 0.52-0.86; P = .0016)].4 In patients who were positive for del(17)p, a TP53 mutation, or both, the effect is particularly pronounced. There was significantly greater PFS benefit at 2-years with zanubrutinib compared with ibrutinib among this subset of patients [at 72.6% vs 54.6% (HR, 0.53; 95% CI, 0.31-0.88].3 Numbers were relatively small here, as there were only 60 patients represented, but these data were compelling for the sustained benefit [of zanubrutinib] in this higher risk group of patients.
What safety data are important to highlight from this study?
There were both fewer progression events in the zanubrutinib arm and fewer adverse events that lead to toxicity….3 In terms of the safety, most of these patients did not require any significant treatment discontinuation. The discontinuations were seen in 15.4% in the zanubrutinib arm and 22.2% in the ibrutinib arm, while the dose interruptions were more common with ibrutinib [at 56.8% compared with 50.0% of patients on zanubrutinib]. The rate of dose reductions was also more common with ibrutinib compared with zanubrutinib at 17.0% vs 12.3%, respectively.3
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
April 26th 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Read More
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More